Results 81 to 90 of about 1,113 (191)

Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren’s syndrome-related keratopathy: a case report

Journal of Medical Case Reports, 2019
Background In this report, we present the results of a severe case of Sjögren’s syndrome-related keratopathy after fluocinolone acetonide 190-μg intravitreal implant (Iluvien®; Alimera Sciences Inc.) therapy.
Joanna Wasielica-Poslednik, Norbert Pfeiffer, Adrian Gericke   +2 more
doaj   +1 more source

Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza: [PDF]

, 2017
Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidenceIntroductionTreatment options for macular edema include intravitreal corticosteroids.
Luz Irene Urbina, Marco Marchetti, Marco Oradei, Matteo Ruggeri, Pierluigi Navarra   +4 more
core   +2 more sources

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®)

Journal of Ophthalmic Inflammation and Infection, 2020
Background The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious ...
Bahram Bodaghi, Quan Dong Nguyen, Glenn Jaffe, Ramin Khoramnia, Carlos Pavesio   +4 more
doaj   +1 more source

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes [PDF]

, 2019
Purpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.
Coelho, João, Malheiro, Luisa, Meireles, Angelina, Melo Beirão, João, Pessoa, Bernardete   +4 more
core   +1 more source

ILUVIEN ^® Technology in the Treatment of center-involving Diabetic Macular edema: a Review of the Literature [PDF]

Therapeutic Delivery, 2018
Diabetic macular edema (DME) is one of the major causes of blindness, caused primarily by hyperglycemia and results from multiple pathological processes mostly secondary to increased levels of VEGF and other inflammatory cytokines. DME management includes control of systemic risk factors together with laser photocoagulation, frequent intraocular ...
openaire   +2 more sources

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

BMJ Open Ophthalmology, 2020
Objective To assess the real-world effectiveness and safety of single injection of a fluocinolone acetonide (FAc) implant in previously treated patients with recurrent diabetic macular oedema (DMO) over a 36-month follow-up period.Methods and Analysis ...
Muna Ahmed, Christine Putri, Hibba Quhill, Fahd Quhill   +3 more
doaj   +1 more source

Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant – A Case Report

Ophthalmology and Therapy, 2019
In January 2013, a 54-year-old pseudophakic woman was referred to the ocular inflammation clinic with a diagnosis of panuveitis, already on oral cyclosporine (100 mg/day) since 2010.
Jorge Meira, Carolina Madeira, Fernando Falcão-Reis, Luís Figueira   +3 more
doaj   +1 more source

Letter to the Editor Regarding the “Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis” Article [Letter]

Clinical Ophthalmology, 2020
Kasserine Taylor,1 Michael W Stewart2 1Department of Ophthalmology, Mayo Clinic Florida, Jacksonville, FL, USA; 2Cornell University, Ithaca, NY, USACorrespondence: Michael W StewartDepartment of Ophthalmology, Mayo Clinic Florida, 4500 San Pablo Road ...
Taylor K, Stewart MW
doaj  

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

BMC Health Services Research, 2019
Background Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitreal vascular ...
Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi, Samuel Aballéa   +5 more
doaj   +1 more source

Use of flucinolone acetonide for patients with diabetic macular oedema:patient selection criteria and early outcomes in real world setting [PDF]

, 2016
Introduction: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies.
Ajay Bhatnagar, Andrej Kidess, CS Brand, D Boyer, DM Brown, DS Boyer, DS Levin, E Chew, Fahad Quhill, Ibrahim Elaraoud, JA Wells, JW Yau, Marie Tsaloumas, MJ Elman, NZ Gregori, PA Campochiaro, PA1 Campochiaro, Walter Andreatta, Yit Yang   +18 more
core   +1 more source